{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T21:56:41Z","timestamp":1776808601001,"version":"3.51.2"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s11912-020-0866-3","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T18:02:49Z","timestamp":1579888969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advances in Therapy for Relapsed or Refractory Hodgkin Lymphoma"],"prefix":"10.1007","volume":"22","author":[{"given":"Yun","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine S.","family":"Diefenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"866_CR1","unstructured":"Cancer Stat Facts: Hodgkin Lymphoma. NIH, Natl Cancer Institute, SEER Data. at https:\/\/seer.cancer.gov\/statfacts\/html\/hodg.html."},{"key":"866_CR2","first-page":"497","volume":"2009","author":"J Kuruvilla","year":"2009","unstructured":"Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. ASH Education Program Book. 2009;2009:497\u2013506.","journal-title":"ASH Education Program Book"},{"key":"866_CR3","first-page":"265","volume":"58","author":"LV Filatova","year":"2012","unstructured":"Filatova LV, Tarasenkova AA, Gershanovich ML, Semiglazov T. Relapse in Hodgkin lymphoma. Vopr Onkol. 2012;58:265\u201374.","journal-title":"Vopr Onkol"},{"key":"866_CR4","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"866_CR5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051\u20134.","journal-title":"Lancet"},{"key":"866_CR6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","volume":"97","author":"CH Moskowitz","year":"2001","unstructured":"Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood. 2001;97:616\u201323.","journal-title":"Blood"},{"issue":"Suppl 1","key":"866_CR7","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/annonc\/mdg703","volume":"14","author":"MS Hertzberg","year":"2003","unstructured":"Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease. Ann Oncol. 2003;14(Suppl 1):i11\u20136.","journal-title":"Ann Oncol"},{"key":"866_CR8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/annonc\/mdf221","volume":"13","author":"A Josting","year":"2002","unstructured":"Josting A, Rudolph C, Reiser M, Mapara M, Sieber M, Kirchner HH, et al. Time-intensified dexamethasone\/cisplatin\/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin\u2019s disease. Ann Oncol. 2002;13:1628\u201335.","journal-title":"Ann Oncol"},{"key":"866_CR9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1023\/A:1026454831340","volume":"10","author":"J Aparicio","year":"1999","unstructured":"Aparicio J, Segura A, Garcera S, et al. ESHAP is an active regimen for relapsing Hodgkin\u2019s disease. Ann Oncol. 1999;10:593\u20135.","journal-title":"Ann Oncol"},{"key":"866_CR10","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/annonc\/mdg496","volume":"14","author":"T Baetz","year":"2003","unstructured":"Baetz T, Belch A, Couban S, Imrie K, Yau J, Myers R, et al. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin\u2019s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2003;14:1762\u20137.","journal-title":"Ann Oncol"},{"key":"866_CR11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/annonc\/mdm090","volume":"18","author":"NL Bartlett","year":"2007","unstructured":"Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin\u2019s lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071\u20139.","journal-title":"Ann Oncol"},{"key":"866_CR12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","volume":"92","author":"A Santoro","year":"2007","unstructured":"Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma. Haematologica. 2007;92:35\u201341.","journal-title":"Haematologica"},{"key":"866_CR13","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2010.30.5771","volume":"28","author":"A Josting","year":"2010","unstructured":"Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin\u2019s lymphoma. J Clin Oncol. 2010;28:5074\u201380.","journal-title":"J Clin Oncol"},{"key":"866_CR14","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","volume":"119","author":"CH Moskowitz","year":"2012","unstructured":"Moskowitz CH, Matasar MJ, Zelenetz AD, Nimer SD, Gerecitano J, Hamlin P, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood. 2012;119:1665\u201370.","journal-title":"Blood"},{"key":"866_CR15","unstructured":"ADCETRIS [EU summary of product characteristics]. Taastrup, Denmark: Takeda Pharma A\/S; 2015."},{"key":"866_CR16","unstructured":"ADCETRIS [US package insert]. Bothell, WA: Seattle Genetics, 2016."},{"key":"866_CR17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","volume":"30","author":"PD Senter","year":"2012","unstructured":"Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012;30:631\u20137.","journal-title":"Nat Biotechnol"},{"key":"866_CR18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","volume":"10","author":"R Horie","year":"1998","unstructured":"Horie R, Watanabe T. CD30: expression and function in health and disease. Semin Immunol. 1998;10:457\u201370.","journal-title":"Semin Immunol"},{"key":"866_CR19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/299065a0","volume":"299","author":"U Schwab","year":"1982","unstructured":"Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299:65\u20137.","journal-title":"Nature"},{"key":"866_CR20","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood-2018-99-112235","volume":"132","author":"A Hagenbeek","year":"2018","unstructured":"Hagenbeek A, Zijlstra JM, Plattel WJ, et al. Combining brentuximab vedotin with DHAP as salvage treatment in relapsed\/refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study. Blood. 2018;132:2923.","journal-title":"Blood"},{"key":"866_CR21","first-page":"2806","volume":"130","author":"RD Cassaday","year":"2017","unstructured":"Cassaday RD, Fromm JR, Cowan AJ, et al. Radiographic and high-throughput sequencing (HTS)-based response assessment after brentuximab vedotin (BV) plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed\/refractory (Rel\/ref) classical Hodgkin lymphoma (cHL): updated results of a phase I\/II trial. Blood. 2017;130:2806.","journal-title":"Blood"},{"key":"866_CR22","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","volume":"30","author":"R Garcia-Sanz","year":"2019","unstructured":"Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group). Ann Oncol. 2019;30:612\u201320.","journal-title":"Ann Oncol"},{"key":"866_CR23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","volume":"132","author":"AS LaCasce","year":"2018","unstructured":"LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132:40\u20138.","journal-title":"Blood"},{"key":"866_CR24","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/bloodadvances.2019000123","volume":"3","author":"M Picardi","year":"2019","unstructured":"Picardi M, Della Pepa R, Giordano C, Pugliese N, Mortaruolo C, Trastulli F, et al. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma. Blood Adv. 2019;3:1546\u201352.","journal-title":"Blood Adv"},{"key":"866_CR25","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853\u201362.","journal-title":"Lancet"},{"key":"866_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","volume":"134","author":"P Armand","year":"2019","unstructured":"\u2022 Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134:22\u20139 Although the data from this phase II trial of pembrolizumab, which showed an 18-month PFS and OS of 82% and 100%, respectively, are promising, the use of PD-1 blockade in the post-ASCT setting is limited by its adverse events.","journal-title":"Blood"},{"key":"866_CR27","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"866_CR28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdx791","volume":"29","author":"AF Herrera","year":"2018","unstructured":"Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018;29:724\u201330.","journal-title":"Ann Oncol"},{"key":"866_CR29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"\u2022\u2022 Connors JM, Jurczak W, Straus DJ, et al. Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378:331\u201344 The ECHELON-1 trial, which showed a difference of 4.9 percentage points in modified 2-year PFS favoring A+AVD over ABVD, led to the FDA approval of BV as a frontline therapy in combination with chemotherapy in advanced stage HL. The impact of integrating BV into earlier lines of therapy on the role of BV as a salvage therapy is yet to be determined.","journal-title":"N Engl J Med"},{"key":"866_CR30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","volume":"7","author":"NL Bartlett","year":"2014","unstructured":"Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.","journal-title":"J Hematol Oncol"},{"key":"866_CR31","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34:2690\u20137.","journal-title":"J Clin Oncol"},{"key":"866_CR32","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","volume":"18","author":"MR Green","year":"2012","unstructured":"Green MR, Rodig S, Juszczynski P, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18:1611\u20138.","journal-title":"Clin Cancer Res"},{"key":"866_CR33","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116:3268\u201377.","journal-title":"Blood"},{"key":"866_CR34","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, et al. Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36:1428\u201339.","journal-title":"J Clin Oncol"},{"key":"866_CR35","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125\u201332.","journal-title":"J Clin Oncol"},{"key":"866_CR36","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood.V126.23.585.585","volume":"126","author":"CS Diefenbach","year":"2015","unstructured":"Diefenbach CS, Hong F, Cohen JB, et al. Preliminary safety and efficacy of the combination of brentuximab vedotin and ipilimumab in relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412). Blood. 2015;126:585.","journal-title":"Blood"},{"key":"866_CR37","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood.V128.22.1106.1106","volume":"128","author":"CS Diefenbach","year":"2016","unstructured":"Diefenbach CS, Hong F, David KA, et al. Title: a phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412 arms D and E). Blood. 2016;128:1106.","journal-title":"Blood"},{"key":"866_CR38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2018-99-115390","volume":"132","author":"C Diefenbach","year":"2018","unstructured":"\u2022\u2022 Diefenbach C, Hong F, Ambinder RF, et al. A phase I study with an expansion cohort of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed\/refractory hodgkin lymphoma: a trial of the ECOG-ACRIN research group (E4412: Arms G-I). Blood. 2018;132:679 In the E4412 trial, the triplet combination of BV, ipilimumab and nivolumab was generally well-tolerated and showed the ORR of 95% and CR rate of 79% in R\/R HL patients. The follow-up phase II trial comparing the combination of BV and nivolumab to the triplet is ongoing.","journal-title":"Blood"},{"key":"866_CR39","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","volume":"131","author":"AF Herrera","year":"2018","unstructured":"\u2022\u2022 Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131:1183\u201394 Similarly in this phase I\/II trial, the doublet of BV and nivolumab was well-tolerated and showed an ORR of 82% with CR rate of 61%, confirming the efficacy and safety of combining BV with immunotherapy.","journal-title":"Blood"},{"key":"866_CR40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clml.2016.09.008","volume":"17","author":"M Levis","year":"2017","unstructured":"Levis M, Piva C, Filippi AR, et al. Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin's lymphoma with incomplete response before autologous stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2017;17:14\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"866_CR41","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","volume":"100","author":"LS Constine","year":"2018","unstructured":"Constine LS, Yahalom J, Ng AK, et al. The role of radiation therapy in patients with relapsed or refractory Hodgkin lymphoma: guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2018;100:1100\u201318.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"866_CR42","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","volume":"54","author":"S Arai","year":"2013","unstructured":"Arai S, Fanale M, deVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma. 2013;54:2531\u20133.","journal-title":"Leuk Lymphoma"},{"key":"866_CR43","doi-asserted-by":"crossref","unstructured":"Ramos CA, Bilgi M, Gerken C, et al. CD30-chimeric antigen receptor (CAR) T cells for therapy of hodgkin lymphoma (HL). Abstract #79 Presented at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, February 23, 2019; Houston, TX 2019.","DOI":"10.1016\/j.bbmt.2018.12.145"},{"key":"866_CR44","doi-asserted-by":"crossref","unstructured":"Grover NS, Park SI, Ivanova A, et al. A phase Ib\/II study of anti-CD30 chimeric antigen receptor T cells for relapsed\/refractory CD30+ lymphomas. Abstract #83 Presented at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR, February 23, 2019; Houston, TX 2019.","DOI":"10.1016\/j.bbmt.2018.12.149"},{"issue":"Suppl 1","key":"866_CR45","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10637-010-9596-y","volume":"28","author":"M Dickinson","year":"2010","unstructured":"Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Investig New Drugs. 2010;28(Suppl 1):S3\u201320.","journal-title":"Investig New Drugs"},{"key":"866_CR46","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197\u2013203.","journal-title":"J Clin Oncol"},{"key":"866_CR47","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/10428194.2017.1359741","volume":"59","author":"B Hu","year":"2018","unstructured":"Hu B, Younes A, Westin JR, et al. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma. 2018;59:863\u201370.","journal-title":"Leuk Lymphoma"},{"key":"866_CR48","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","volume":"2","author":"V Kotla","year":"2009","unstructured":"Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.","journal-title":"J Hematol Oncol"},{"key":"866_CR49","doi-asserted-by":"crossref","first-page":"5119","DOI":"10.1182\/blood-2011-07-362475","volume":"118","author":"TA Fehniger","year":"2011","unstructured":"Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011;118:5119\u201325.","journal-title":"Blood"},{"key":"866_CR50","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood.V124.21.3099.3099","volume":"124","author":"B Christian","year":"2014","unstructured":"Christian B, Wei L, Sexton J, et al. A phase I\/II trial of the histone deacetylase (HDAC) inhibitor, panobinostat, in combination with lenalidomide in patients with relapsed\/refractory Hodgkin\u2019s lymphoma (HL). Blood. 2014;124:3099.","journal-title":"Blood"},{"key":"866_CR51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.4558","volume":"237","author":"A Carbone","year":"2015","unstructured":"Carbone A, Gloghini A, Castagna L, Santoro A, Carlo-Stella C. Primary refractory and early-relapsed Hodgkin\u2019s lymphoma: strategies for therapeutic targeting based on the tumour microenvironment. J Pathol. 2015;237:4\u201313.","journal-title":"J Pathol"},{"key":"866_CR52","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3324\/haematol.2017.180554","volume":"103","author":"E Van Den Neste","year":"2018","unstructured":"Van Den Neste E, Andre M, Gastinne T, et al. A phase II study of the oral JAK1\/JAK2 inhibitor ruxolitinib in advanced relapsed\/refractory Hodgkin lymphoma. Haematologica. 2018;103:840\u20138.","journal-title":"Haematologica"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0866-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-020-0866-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-020-0866-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:48:36Z","timestamp":1611362916000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-020-0866-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["866"],"URL":"https:\/\/doi.org\/10.1007\/s11912-020-0866-3","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"24 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Yun Choi declares that she has no conflict of interest.Catherine S. Diefenbach has received research funding from Bristol-Myers Squibb, Merck, and Seattle Genetics and has received compensation from Bristol-Myers Squibb, Merck, and Seattle Genetics for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"6"}}